Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079271 | 0.86 | TSHR (0.47) | TSHRKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL29906642 | 0.79 | TSHR (0.48) | TSHRKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1669584 | 0.79 | TSHR (0.48) | TSHRKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL16433573 | 0.79 | KDM4E (0.48) | TSHRKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2327456 | 0.78 | TSHR (0.47) | TSHRKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7844021 | 0.78 | TSHR (0.47) | TSHRKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL31351961 | 0.78 | TSHR (0.47) | TSHRKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL20345734 | 0.77 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL14054019 | 0.77 | OPRK1 (0.46) | TSHRKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL29603610 | 0.77 | OPRK1 (0.46) | TSHRKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| EP-3562306-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2025-02-26 | — | — | EP | disclosed |
| US-12098148-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2024-09-24 | — | — | US | disclosed |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) | 2024-03-05 | — | — | US | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2022-01-13 | — | — | US | disclosed |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| CN-112996785-A | Therapeutic compounds | 希四克斯探索有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| EP-3562306-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | TSHR 2240/4885KDM4E 3875/4885ALDH1A1 457/4885 |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | TSHR 2240/4885KDM4E 3875/4885ALDH1A1 457/4885 |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | TSHR 2240/4885KDM4E 3875/4885ALDH1A1 457/4885 |
| US-12098148-B2 | Therapeutic compounds | NFE2L2, KEAP1, NQO1 | TSHR 4051/4885KDM4E 3963/4885ALDH1A1 307/4885 |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | TSHR 2240/4885KDM4E 3875/4885ALDH1A1 457/4885 |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | TSHR 4051/4885KDM4E 3963/4885ALDH1A1 307/4885 |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | TSHR 2240/4885KDM4E 3875/4885ALDH1A1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.